Ficarino H, Cage B, Osula JP, Heatherly A, Chu D, Reddy S, Bhatia S, Hollis R. Deficiencies in germline genetic testing in young-onset colorectal cancer patients.
Am J Surg 2024;
232:126-130. [PMID:
38302366 PMCID:
PMC11090699 DOI:
10.1016/j.amjsurg.2024.01.022]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 01/21/2024] [Accepted: 01/24/2024] [Indexed: 02/03/2024]
Abstract
BACKGROUND
Young-onset colorectal cancer (YO-CRC) patients have high rates of pathologic genetic variants on germline testing, however it is unclear what factors are associated with genetic testing completion.
METHODS
We performed a retrospective review of YO-CRC patients aged ≤50 years between 2014 and 2021 who received the entirety of their cancer care at a single institution. The primary outcome was completion of germline multigene panel testing. Variables were examined for association with germline multigene panel testing.
RESULTS
Among 100 YO-CRC patients, only 31 % (n = 31) completed genetic testing. Testing rates did not differ by colorectal cancer stage but were significantly higher among patients who received chemotherapy (39.8 % vs 5.9 %; p = 0.01) and in patients with increasing number of relatives with a family history of cancer (p < 0.01).
CONCLUSIONS
Only one-third of YO-CRC patients completed genetic testing. Patients seen by oncology or with increasingly strong family cancer history were more likely to complete genetic testing.
Collapse